Cargando…
Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines
BACKGROUND: Hydroxychloroquine (HCQ) retinopathy may be more common than previously recognized; recent ophthalmology guidelines have revised recommendations from ideal body weight (IBW)-based dosing to actual body weight (ABW)-based dosing. However, contemporary HCQ prescribing trends in the UK rema...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034317/ https://www.ncbi.nlm.nih.gov/pubmed/29976231 http://dx.doi.org/10.1186/s13075-018-1634-8 |
_version_ | 1783337856266141696 |
---|---|
author | Jorge, April M. Melles, Ronald B. Zhang, Yuqing Lu, Na Rai, Sharan K. Young, Lucy H. Costenbader, Karen H. Ramsey-Goldman, Rosalind Lim, S. Sam Esdaile, John M. Clarke, Ann E. Urowitz, M. B. Askanase, Anca Aranow, Cynthia Petri, Michelle Choi, Hyon |
author_facet | Jorge, April M. Melles, Ronald B. Zhang, Yuqing Lu, Na Rai, Sharan K. Young, Lucy H. Costenbader, Karen H. Ramsey-Goldman, Rosalind Lim, S. Sam Esdaile, John M. Clarke, Ann E. Urowitz, M. B. Askanase, Anca Aranow, Cynthia Petri, Michelle Choi, Hyon |
author_sort | Jorge, April M. |
collection | PubMed |
description | BACKGROUND: Hydroxychloroquine (HCQ) retinopathy may be more common than previously recognized; recent ophthalmology guidelines have revised recommendations from ideal body weight (IBW)-based dosing to actual body weight (ABW)-based dosing. However, contemporary HCQ prescribing trends in the UK remain unknown. METHODS: We examined a UK general population database to investigate HCQ dosing between 2007 and 2016. We studied trends of excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW) and determined their independent predictors using multivariable logistic regression analyses. RESULTS: Among 20,933 new HCQ users (78% female), the proportions of initial HCQ excess dosing declined from 40% to 36% using IBW and 38% to 30% using ABW, between 2007 and 2016. Among these, 47% of women were excess-dosed (multivariable OR 12.52; 95% CI 10.99–14.26) using IBW and 38% (multivariable OR 1.98; 95% CI,1.81–2.15) using ABW. Applying IBW, 37% of normal and 44% of obese patients were excess-dosed; however, applying ABW, 53% of normal and 10% of obese patients were excess-dosed (multivariable ORs = 1.61 and 0.1 (reference = normal); both p < 0.01). Long-term HCQ users showed similar excess dosing. CONCLUSION: A substantial proportion of HCQ users in the UK, particularly women, may have excess HCQ dosing per the previous or recent weight-based guidelines despite a modest decline in recent years. Over half of normal-BMI individuals were excess-dosed per the latest guidelines. This implies the potential need to reduce dosing for many patients but also calls for further research to establish unifying evidence-based safe and effective dosing strategies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13075-018-1634-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6034317 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60343172018-07-09 Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines Jorge, April M. Melles, Ronald B. Zhang, Yuqing Lu, Na Rai, Sharan K. Young, Lucy H. Costenbader, Karen H. Ramsey-Goldman, Rosalind Lim, S. Sam Esdaile, John M. Clarke, Ann E. Urowitz, M. B. Askanase, Anca Aranow, Cynthia Petri, Michelle Choi, Hyon Arthritis Res Ther Research Article BACKGROUND: Hydroxychloroquine (HCQ) retinopathy may be more common than previously recognized; recent ophthalmology guidelines have revised recommendations from ideal body weight (IBW)-based dosing to actual body weight (ABW)-based dosing. However, contemporary HCQ prescribing trends in the UK remain unknown. METHODS: We examined a UK general population database to investigate HCQ dosing between 2007 and 2016. We studied trends of excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW) and determined their independent predictors using multivariable logistic regression analyses. RESULTS: Among 20,933 new HCQ users (78% female), the proportions of initial HCQ excess dosing declined from 40% to 36% using IBW and 38% to 30% using ABW, between 2007 and 2016. Among these, 47% of women were excess-dosed (multivariable OR 12.52; 95% CI 10.99–14.26) using IBW and 38% (multivariable OR 1.98; 95% CI,1.81–2.15) using ABW. Applying IBW, 37% of normal and 44% of obese patients were excess-dosed; however, applying ABW, 53% of normal and 10% of obese patients were excess-dosed (multivariable ORs = 1.61 and 0.1 (reference = normal); both p < 0.01). Long-term HCQ users showed similar excess dosing. CONCLUSION: A substantial proportion of HCQ users in the UK, particularly women, may have excess HCQ dosing per the previous or recent weight-based guidelines despite a modest decline in recent years. Over half of normal-BMI individuals were excess-dosed per the latest guidelines. This implies the potential need to reduce dosing for many patients but also calls for further research to establish unifying evidence-based safe and effective dosing strategies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13075-018-1634-8) contains supplementary material, which is available to authorized users. BioMed Central 2018-07-05 2018 /pmc/articles/PMC6034317/ /pubmed/29976231 http://dx.doi.org/10.1186/s13075-018-1634-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Jorge, April M. Melles, Ronald B. Zhang, Yuqing Lu, Na Rai, Sharan K. Young, Lucy H. Costenbader, Karen H. Ramsey-Goldman, Rosalind Lim, S. Sam Esdaile, John M. Clarke, Ann E. Urowitz, M. B. Askanase, Anca Aranow, Cynthia Petri, Michelle Choi, Hyon Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines |
title | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines |
title_full | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines |
title_fullStr | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines |
title_full_unstemmed | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines |
title_short | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines |
title_sort | hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034317/ https://www.ncbi.nlm.nih.gov/pubmed/29976231 http://dx.doi.org/10.1186/s13075-018-1634-8 |
work_keys_str_mv | AT jorgeaprilm hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines AT mellesronaldb hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines AT zhangyuqing hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines AT luna hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines AT raisharank hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines AT younglucyh hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines AT costenbaderkarenh hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines AT ramseygoldmanrosalind hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines AT limssam hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines AT esdailejohnm hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines AT clarkeanne hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines AT urowitzmb hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines AT askanaseanca hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines AT aranowcynthia hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines AT petrimichelle hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines AT choihyon hydroxychloroquineprescriptiontrendsandpredictorsforexcessdosingperrecentophthalmologyguidelines |